Compare AbCellera Biologics Inc (ABCL) vs Weibo Corp (WB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Weibo Corp — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Weibo Corp trades at $7.6 (market cap $1.85B). The key difference: AbCellera Biologics Inc is the larger of the two by market cap, and Weibo Corp pays a 8.16% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | WB | |
|---|---|---|
Market Cap | $2.35B | $1.85B |
Sector | Health | Media |
52-Week High | $8.12 | $12.83 |
52-Week Low | $2.78 | $7.20 |
Enterprise Value | $1.99B | $1.12B |
Dividend Yield | — | 8.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Weibo (WB) trades at $7.47, up 1.49% today, with a bullish technical signal and strong fundamentals including a 25.55% net margin and 10.33% ROE. Recent quarterly earnings missed expectations, but the company maintains robust cash flow and a high dividend yield. Valuation metrics appear attractive with a P/E of 5.29 and P/B of 0.48, while analyst sentiment is mixed with 45% buy ratings.
The outlook balances deep value against competitive pressures. The stock offers significant upside if monetization improves, but faces risks from user engagement declines and rivalry with Douyin. Near-term catalysts include Q2 2026 earnings and dividend payments, though consistent EPS misses warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
